Monday Morning Financial report had a good article on ARNA from a top analyst, overall very favorable expecting a 50% gain on approval, and feels some of the price has baked in value already since FDA approval. Comments he made about the DEA..........a huge crack down on the drug pill mills writing scripts for class two and three drugs being abused is a current target from the administration for policy enforcement. The author claims this has taken most of the resources of the DEA to focus on chasing down this criminal abuse of illegal scripts making their way to the street. He claims this is the main reason for the delay in approval of new drugs coming to market. Basically they dropped one ball to go chasing after another as their priority, and don't really care much for the fate of new pending drug approval's before them. In short, my view is they don't have the ability to multi-task, their resources to accomplish the scope of their job, and function in a poor manner like most government agency's.
Well the problem is this product has been approved by the FDA, and YES the DEA has already recommended a Class IV label. With that in place this should be moved through quickly as it is not a drug these boys are going to be chasing down for bad Rx's. Just more government bull sheet and inefficiencies - it is pathetic how they operate.